OTCMKTS:SIGY Sigyn Therapeutics (SIGY) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 06/24/2026 02:41 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendEarningsHeadlinesSEC FilingsBuy This Stock About Sigyn Therapeutics Stock (OTCMKTS:SIGY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sigyn Therapeutics alerts:Sign Up Key Stats Today's Range$0.03▼$0.0450-Day Range$0.03▼$0.0552-Week Range$0.01▼$5.00Volume36,682 shsAverage Volume10,292 shsMarket Capitalization$88.90 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California. Read More Sigyn Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreSIGY MarketRank™: Sigyn Therapeutics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Sigyn Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sigyn Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sigyn Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Sigyn Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.84% of the float of Sigyn Therapeutics has been sold short.Short Interest Ratio / Days to CoverSigyn Therapeutics has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sigyn Therapeutics has recently decreased by 51.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSigyn Therapeutics does not currently pay a dividend.Dividend GrowthSigyn Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Sigyn Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sigyn Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders78.46% of the stock of Sigyn Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions10.01% of the stock of Sigyn Therapeutics is held by institutions.Read more about Sigyn Therapeutics' insider trading history. Receive SIGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SIGY Stock News HeadlinesSIGY Sigyn Therapeutics Inc.May 20, 2026 | seekingalpha.comSigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTEApril 2, 2026 | finance.yahoo.com2,000 missiles didn't hit Iran. They hit China.Iran sold 90% of its oil to China. Venezuela secretly shipped 80% of its exports to the same buyer. Within 60 days, America cut both supply lines - starving China's AI power grid of the cheap, endless fuel it needs to compete. Now all that energy flows through a single American chokepoint: one company, 140,000 miles of steel, and no competition. Dylan Jovine has identified the stock at the center of this strategy, along with three ascending price targets. | Behind the Markets (Ad)Sigyn Therapeutics Delays Annual SEC FilingMarch 31, 2026 | tipranks.comScientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory DiseasesMarch 24, 2026 | finance.yahoo.comSigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale InitiativesMarch 13, 2026 | finance.yahoo.comSigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate InitiativesJanuary 15, 2026 | finance.yahoo.comThe Emergence of Blood Purification Devices to Treat Cardiovascular DiseaseJanuary 7, 2026 | theglobeandmail.comSee More Headlines SIGY Stock Analysis - Frequently Asked Questions How have SIGY shares performed this year? Sigyn Therapeutics' stock was trading at $1.7099 at the beginning of 2026. Since then, SIGY stock has decreased by 98.0% and is now trading at $0.0350. How were Sigyn Therapeutics' earnings last quarter? Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) released its quarterly earnings data on Tuesday, December, 2nd. The company reported $0.49 earnings per share for the quarter. How do I buy shares of Sigyn Therapeutics? Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sigyn Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sigyn Therapeutics investors own include Rocket Lab (RKLB), Archer Aviation (ACHR), Atlas Lithium (ATLX), OriginOil (OCLN), BlackSky Technology (BKSY). Company Calendar Last Earnings12/02/2025Today6/25/2026Next Earnings (Estimated)8/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolOTCMKTS:SIGY CIK1642159 Webwww.sigyntherapeutics.com Phone(619) 353-0800FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.34 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-3,743.20% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.78) per share Price / Book-0.01Miscellaneous Outstanding Shares2,540,000Free Float548,000Market Cap$88.90 thousand OptionableNot Optionable Beta-0.06 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:SIGY) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersSpaceX IPO “cancelled”?SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...InvestorPlace | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe EPA just put a kill switch on Elon’s empireA federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredGrab it and keep itSimple Options Trading For Beginners is currently available as a free download - a guide normally priced at $2...Profits Run | SponsoredMillionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigyn Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigyn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
